Short answer
Vaxcyte, Inc. (PCVX) filed its Q3 2025 10-Q quarterly report on Nov 4, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$213M
- −106.4% YoY · −27.8% QoQ
- EPS (diluted)
- −$1.57
- −89.2% YoY · −28.7% QoQ
Source: XBRL data from the Vaxcyte, Inc. (PCVX) Q3 2025 10-Q on SEC EDGAR. USD.
Vaxcyte, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk: Delays in drug substance manufacturing campaign due to Lonza capacity constraints impacting VAX-24 IND timelines
- Updated financial risk: Net losses $212.8M Q3 2025 vs $103.1M Q3 2024; accumulated deficit $1.9B as of September 30, 2025
- Regulatory risk: FDA may challenge VAX-31 Phase 3 Chemistry, Manufacturing and Controls strategy causing delays and added costs
- Operational risk: Prioritization shift suspending VAX-A1, VAX-GI preclinical advancement and discontinuing VAX-PG due to efficacy concerns
- Financial risk: Cash, cash equivalents and investments of $2.7B sufficient for 12+ months but need substantial future funding amid volatile markets
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Vaxcyte, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.